ArticleLipids in health and disease2025
NSUN2 knockdown ameliorates hepatic glucose and lipid metabolism disorders in type 2 diabetes mellitus through the Inhibition of ACSL6 m5C methylation.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- NSUN2-Mediated mInternational journal of general medicine · 2026Review
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
- Long-chain acyl-CoA synthetases: biological functions, diseases and therapeutic targets.Molecular biomedicine · 2025Review
- NSUN2-mediated mJournal of diabetes investigation · 2025Article
- Recent research advances in RNA m5C methylation modification in liver diseases.Frontiers in molecular biosciences · 2025Review
- Roles and mechanisms of NSUN2-mediated RNA mFrontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHyperglycemia and dyslipidemia characterize type 2 diabetes mellitus (T2DM). The impact of 5-methylcytosine (m5C) on liver glucose and lipid regulation in T2DM is unclear. In this study, the regulation of liver glucose and lipid metabolism by m5C methylation in a T2DM model was investigated.
methodsC57BL/6 mice developed T2DM via a high-fat diet (HFD) and streptozotocin (STZ) administration. Quantitative real-time PCR was performed to assess m5C-associated gene expression in HFD-fed mice and NSUN2 levels in clinical samples. Glucose metabolism was assessed via glucose metabolism function tests. Lipid metabolic parameters were evaluated through pathological analysis and measurements of biochemical indicators in HFD-fed mice. Mechanistic investigations utilized methylated RNA immunoprecipitation (MeRIP), RNA immunoprecipitation (RIP) and RIP.
resultsNSUN2 expression was significantly upregulated in both T2DM clinical samples and HFD-fed mice. NSUN2 knockdown enhanced glucose tolerance and pyruvate metabolism, ameliorated insulin resistance, and suppressed hepatic lipid accumulation in HFD-fed mice. Mechanistically, NSUN2 depletion reduced ACSL6 expression by inhibiting m5C modification of ACSL6 mRNA. Furthermore, the metabolic improvements in HFD-fed mice following NSUN2 knockdown were partially reversed by ACSL6 overexpression.
conclusionThis study demonstrated that NSUN2 mediates glucose and lipid metabolism dysregulation in the liver during T2DM through m5C-dependent ACSL6. These findings highlight NSUN2 as a viable target for innovative T2DM treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.